Clinical trial
Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or…
NCT00026416 · Herbert Irving Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00026416 |
|---|---|
| Title | Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma |
| Official title | Phase II Study of Low-Dose Interferon Alfa 2B (Schering Plough) Plus Thalidomide (Celgene) for Patients With Resected High-Risk Soft Tissue Sarcoma |
| Lead sponsor | Herbert Irving Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | recombinant interferon alfa, thalidomide, adjuvant therapy |
| Start date | Oct 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: